Hirotsugu Uemura is an expert in Oncology at Kindai University Hospital (Japan). As of June 2026, ScienceLeadR ranks Hirotsugu Uemura in the top 1% of experts worldwide for Kidney Neoplasms, Urologic Neoplasms and Urogenital Neoplasms. Hirotsugu Uemura has authored 490 publications, the most recent in 2026, and is an investigator in 24 clinical trials. SLR score: 1,730 (community average: 125). How the SLR is computed.

LeadR Profile

Hirotsugu Uemura Kindai University Hospital Japan
1 730 ScienceLeadR Reputation 1730
Network Map

Oncology

Subspecialties: Urology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026

Source: PubMed

Kindai University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 490

Citations

Citations: 17 998 1st author: 27 Last author: 218 Unique author: 2


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Therapeutic effects of imidazoline 2 receptor activation on lower urinary tract dysfunction in a mouse model of spinal cord injury.
PMID 41902699 — urinary bladder, spinal cord, urinary tract, baths, urodynamics, spinal cord injuries, imidazolines, therapeutics, pharmaceutical vehicles, spine
Am J Physiol Renal Physiol20260
A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.
PMID 41841331 — cells, progression-free survival, carcinoma, renal cell, drug-related side effects and adverse reactions, nivolumab, therapeutics, ipilimumab, prospective studies
Int J Urol20260
Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer: Results From a 3-Year Interim Analysis of the J-ROCK Study.
PMID 41524484 — docetaxel, androgens, neoplasms, prostate, hormones, prostatic neoplasms, therapeutics, prognosis
Prostate20260
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study.
PMID 41292059 — cells, safety, carcinoma, renal cell, drug-related side effects and adverse reactions, nivolumab, therapeutics, ipilimumab, prospective studies
Int J Urol20250
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study.
PMID 41120017 — androgens, neoplasms, prostate, hormones, prostatic neoplasms, therapeutics
Ann Oncol Top journal20250

Clinical Studies 24

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 1

By phase:

Phase 3 14
Phase 2 4
N/A 2
Phase 1 2
Phase 1/Phase 2 1
Phase 4 1

By status:

Completed 18
Active not recruiting 5
Recruiting 1

By type:

Interventional 22
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 1
multicentricup10 19

Main Topics

LeadR Networks

Main global connection map